1. Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes – a tertiary care center experience
- Author
-
Kapil Soni, Aparna Das, Vidhu Sharma, Amit Goyal, Bikram Choudhury, Ankita Chugh, Deepak Kumar, Taruna Yadav, Vidhi Jain, Ashwini Agarwal, Mayank Garg, Kavita Bhatnagar, Poonam Elhence, Pradeep Kumar Bhatia, Mahendra Kumar Garg, and Sanjeev Misra
- Subjects
Male ,Antifungal Agents ,SARS-CoV-2 ,COVID-19 ,Article ,Tertiary Care Centers ,Treatment ,Staging protocol ,Infectious Diseases ,Orbital Diseases ,ROCM (rhino-orbito-cerebral mucormycosis) ,Humans ,Mucormycosis ,Female ,Amphotericin ,Eye Infections, Fungal ,Pandemics ,Outcome - Abstract
Objective To evaluate the outcome of patients with ROCM (Rhino-orbito-cerebral mucormycosis) following their medical and surgical management. Materials and methods It is a prognostic study based in a tertiary care center in North-Western India. Patients who developed ROCM post COVID-19 infection from 1st September 2020 to 30th June 2021 were included in this study. Surgical debridement and administration of antifungal therapy was done for the post-COVID-19 ROCM patients. Disease progression and survival was studied up to 5 months of follow-up in the second wave. Results A total of 145 ROCM patients were included. The mean age at presentation, male: female ratio was 48.2 years and 2:1 respectively. As per our proposed new staging system and treatment strategy, the majority of patients belonged to stage II (31.72%) and stage III (31.03%). On a follow-up period of 5 months, 26 (18%) patients have lost their life and rest of the patients are on strict follow-up. Conclusion ROCM is an extremely aggressive fungal infection which rapidly became an epidemic following the COVID-19 pandemic. The diverse and unique presentation led us to evolve a new strategy to classify and manage these patients.
- Published
- 2022
- Full Text
- View/download PDF